Somatostatin analogues for the treatment of enterocutaneous fistulas: A systematic review and meta-analysis

World Journal of Surgery

Volumn 36, Issue 5, 2012, Pages 1016-1029

  Coughlin, Shaun ^a   Roth, Lee ^a   Lurati, Giovanna ^b   Faulhaber, Markus ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; CYCLOPEPTIDE; DRUG DERIVATIVE; GASTROINTESTINAL AGENT; OCTREOTIDE; SOMATOSTATIN;

HUMAN; INTESTINE FISTULA; LENGTH OF STAY; META ANALYSIS; MORTALITY; REOPERATION; REVIEW; STATISTICS; TREATMENT OUTCOME;

GASTROINTESTINAL AGENTS; HUMANS; INTESTINAL FISTULA; LENGTH OF STAY; OCTREOTIDE; PEPTIDES, CYCLIC; REOPERATION; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 84863724326     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-012-1494-3     Document Type: Review

References (23)

1. Evenson AR, Fischer JE (2006) Current management of enterocutaneous fistula. J Gastrointest Surg 10:455-464
2. Hesse U, Ysebaert D, de Hemptinne B (2001) Role of somatostatin-14 and its analogues in the management of gastrointestinal fistulae: clinical data. Gut 49(Suppl 4):iv11-iv21
3. Li-Ling J, Irving M (2001) Somatostatin and octreotide in the prevention of postoperative pancreatic complications and the treatment of enterocutaneous pancreatic fistulas: a systematic review of randomized controlled trials. Br J Surg 88:190-199
4. Koti RS, Gurusamy KS, Fusai G et al (2010) Meta-analysis of randomized controlled trials on the effectiveness of somatostatin analogues for pancreatic surgery: a Cochrane review. HPB 12:155-165
5. Shea BJ, Bouter LM, Peterson J et al (2007) External validation of a measurement tool to assess systematic reviews (AMSTAR). PLoS ONE 2(12):e1350
6. Moher D, Liberati A, Tetzlaff J, The PRISMA Group et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(6):e1000097. doi: 10.1371/journal.pmed1000097
7. Higgins JPT, Green S (eds) (2009) Cochrane handbook for systematic reviews of interventions, version 5.0.2. The Cochrane collaboration (updated Sep 2009) www.cochrane-handbook.org
8. Sacket D, Hayes R, Guyatt G et al. (1991) Clinical epidemiology: a basic science for clinical medicine, 2nd edn. Little Brown & Co., Boston, p 30
9. Guyatt GH, Oxman AD, Kunz R et al (2008) Rating quality of evidence and strength of recommendations. What is "quality of evidence" and why is it important to clinicians? BMJ 336:995-998
10. Dickersin K, Chan S, Chalmers TC et al (1987) Publication bias and clinical trials. Control Clin Trials 4:343-353
11. Gayral F, Campion J, Regimbeau J et al (2009) Randomized, placebo-controlled, double-blind study of the efficacy of lanreotide 30 mg PR in the treatment of pancreatic and enterocutaneous fistulae. Ann Surg 50:872-877
12. Hernandez-Aranda JC, Gallo-Chico B, Flores-Ramirez LA et al (1996) Treatment of enterocutaneous fistula with or without octreotide and parenteral nutrition. Nutr Hosp 11:226-229
13. Isenmann R, Schielke DJ, Morl FK et al (1994) Adjuvant therapy with somatostatin i.v. in postoperative fistulas of the pancreas, gallbladder and small intestine [Adjuvante therapie postoperativer pankreas-, gall- und dunndarmfisteln mit somatostatin i.v. eine multizentrische, randomisierte studie]. Aktuelle Chir 29:96-99
14. Jamil M, Ahmed U, Sobia H (2004) Role of somatostatin analogues in the management of enterocutaneous fistulae. J Coll Phys Surg Pak 14:237-240
15. Leandros E, Antonakis PT, Albanopoulos K et al (2004) Somatostatin versus octreotide in the treatment of patients with gastrointestinal and pancreatic fistulas. Can J Gastroenterol 18:303-306
16. Sancho JJ, di Costanzo J, Nubiola P et al (1995) Randomized double-blind placebo-controlled trial of early octreotide in patients with postoperative enterocutaneous fistula. Br J Surg 82:638-641
17. Scott NA, Finnegan S, Irving MH (1993) Octreotide and postoperative enterocutaneous fistulae: a controlled prospective study. Acta Gastroenterol Belg 56:266-270
18. Torres AJ, Landa JI, Moreno-Azcoita M et al (1992) Somatostatin in the management of gastrointestinal fistulas. A multicenter trial. Arch Surg 127:97-99
19. Scott NA, Finnegan S, Irving MH (1990) Octreotide and gastrointestinal fistulae. Digestion 45(Suppl 1):66-70
20. Atkins D, Best D, Briss PA et al (2004) Grading quality of evidence and strength of recommendations. BMJ 328(7454):1490
21. Guyatt G, Gutterman D, Baumann MH (2006) Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American college of chest physicians task force. Chest 129:174-181
22. * working group (2004) Grading quality of evidence and strength of recommendations. BMJ 328:1490-1494
23. Guyatt G, Oxman A, Vist G et al (2011) GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of bias) and publication bias. J Clin Epidemiol 64:407-415